(Q53244408)

12 May 2018

title

Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. (English)

1 reference

12 May 2018

1 reference

1 reference

1 reference

8

1 reference

12 May 2018

Gerd Mikus

9

1 reference

12 May 2018

author name string

Heike Oberwittler

1

1 reference

12 May 2018

Andreas Hirschfeld-Warneken

2

1 reference

12 May 2018

Roland Wesch

3

1 reference

12 May 2018

Hans Willerich

4

1 reference

12 May 2018

Lenore Teichert

5

1 reference

12 May 2018

Karl-Heinz Lehr

6

1 reference

12 May 2018

Reinhard Ding

7

1 reference

12 May 2018

publication date

1 January 2007

1 reference

12 May 2018

The Journal of Clinical Pharmacology

published in

1 reference

12 May 2018

volume

47

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

70-77

1 reference

12 May 2018

Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Phenomenon of nitrate tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Nitric oxide. Novel biology with clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Systematic overview of warfarin and its drug and food interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Interaction of warfarin with drugs, natural substances, and foods

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Voriconazole potentiates warfarin‐induced prothrombin time prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Absence of a pharmacokinetic interaction between etanercept and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270006294540

21 January 2018

Identifiers

DOI

10.1177/0091270006294540

1 reference

12 May 2018

PubMed ID

17192504

1 reference

12 May 2018